Schistosomiasis Haematobia
Conditions
Brief summary
Open labelled, non randomized study to evaluate the effects of Artemisinin based Combined Therapies(ACTs) on schistosomiasis since Praziquantel (PZQ) which is presently the drug of choice for treating Schistosomiasis (STS), is ineffective on immature stages and there is known parasite resistance. ACTs when combined with PZQ, targeting different stages of the life cycle has shown some effectivity.
Detailed description
Study population included all subjects in study area who signed a written Informed Consent Form diagnosed with Malaria- STS co-infection. Those excluded were treated with PZQ prior 6 weeks, have drug intolerance or pregnant. At Inclusion, Basic Demographic data was recorded and urine samples analysed. During the follow up visits, urine samples were collected on D28 and D42 (6 weeks post treatment). Post treatment assessment was done on urine samples collected on at least two consecutive days and at the end of follow up, all subjects were treated with a single dose pf PZQ (40 mg/kg) as recommended by WHO.
Interventions
Subjects received artesunate-pyronaridine according to their body weight once per day for three days.
DRUGArtemether-Lumefantrine
subjects received artemether-lumefantrine according to their body weight twice per day for three days.
DRUGArtefenomel-Ferroquine
Subject received a single dose of artefenomel-ferroquine according to their body weight
Sponsors
Centre de Recherche Médicale de Lambaréné
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Malaria infection diagnosed by Rapid Diagnostic Tests (RDTs) or thick blood smear * Urinary schistosomiasis diagnosed by presence of Schistosoma haematobium eggs in the urine before malaria treatment * Written informed consent
Exclusion criteria
* Patients treated with PZQ during the previous 6 weeks * Known intolerance /allergy to any study drug * Pregnancy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Egg Reduction Rate (ERR) | Day 28 | Evaluate ERR conferred by ACTs as treatment of infection with Schistosoma hematobia |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Cure Rate (CR) | Day 28 | CR of ACTs on Schistosoma haematobia |
Countries
Gabon
Outcome results
None listed